Skip to main content
Premium Trial:

Request an Annual Quote

Sherlock Biosciences Licenses Ambient Temperature Amplification Tech From Wyss Institute

NEW YORK – Sherlock Biosciences said on Monday that it has licensed a nucleic acid amplification technology that functions at ambient temperatures from Harvard's Wyss Institute. Financial terms of the deal were not disclosed.

The exclusive worldwide license covers technology developed at Wyss in the lab of James Collins, developer of Sherlock's CRISPR-based core technology and a cofounder of the company.

Sherlock plans to combine the method with its CRISPR platform to develop instrument-free diagnostic tests to detect pathogen or disease-related nucleic acids at the point of need.

"The highly stable enzyme-based, multi-component nucleic acid amplification method coming out of Collins' Wyss lab will be a pivotal piece of our technology platform," said Bryan Dechairo, Sherlock's president and CEO, in a statement.

The Specific High-sensitivity Enzymatic Reporter unlocking, or SHERLOCK, technology detects target RNA or DNA molecules with high sensitivity and specificity, and without strict temperature requirements. "By integrating it with this next-generation amplification technology, we will be able to perform the entire detection-amplification-visualization process at ambient temperatures and, importantly, instrument-free," Dechairo added.

Sherlock Biosciences was founded in 2019 to build low-cost, portable diagnostic tests addressing critical unmet needs for patients at home and in low-resource settings using CRISPR and other technologies. Sherlock and the Collins lab have previously collaborated on point-of-care molecular malaria assays.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.